Q32 Bio (QTTB) risk factors

Item 1A of every Q32 Bio Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open QTTB in Gloom →

Q32 Bio's chart, financials and news, free in your browser.Open QTTB in Gloom →

FY2025 10-K risk factors
79 risks7 new11 dropped14 reworded
Q32 Bio added new risks covering Nasdaq minimum equity compliance, AI healthcare regulations, and stock option repricing consequences. The company updated financial figures, including NOLs of $423.3 million and $2.4 million in state R&D tax credits.
Filed Mar 10, 2026
FY2024 10-K risk factors
83 risks
Clinical-stage biotech focused on bempikibart after discontinuing ADX-097 in February 2025. Highly reliant on raising capital, patent protection, and FDA regulatory approvals to survive.
Filed Mar 11, 2025